slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 208,921-208,950
Pages 10,126
Rows per page 30
Component
208,921-208,950 of 303,780
18
Standard clinical trial swimmer plot visualization.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
19
Includes patient enrollment status and breakdown of ORR by prior lines of therapy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
20
Standard clinical trial survival analysis charts (Kaplan-Meier) with 'Number at risk' tables below.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
The slide compares clinical trial data for a specific combination therapy against historical label data for individual components.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
The table compares a small sample size (N=24) against much larger historical cohorts.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
23
The slide uses a side-by-side comparison to highlight the superior ORR, PFS, and OS of CTX-009 compared to historical benchmarks like FOLFOX and TOPAZ-1.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
24
The slide outlines a 2:1 randomized clinical trial structure for a drug combination (CTX-009 + Paclitaxel) versus a control (Paclitaxel).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
25
The slide uses a table for market sizing and a structured layout to contrast 1L and 2L treatment options.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
26
The slide depicts a standard Simon 2-stage design, a common statistical framework in oncology clinical trials.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
27
The slide provides epidemiological data alongside a clinical treatment landscape overview.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
28
The slide uses a three-column layout to represent sequential or parallel development tracks.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
30
Includes a molecular visualization showing the binding site of CTX-471 compared to other antibodies.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
The slide uses a before-and-after visual comparison of CT scans to demonstrate drug efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
32
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
34
The slide uses a process flow diagram to show the transition from testing bispecific formats to the identification of the lead candidate CTX-8371.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
36
The slide shows tumor volume reduction over time, percentage tumor growth inhibition, and individual tumor response curves, highlighting CTX-8371's efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
37
The slide outlines the current progress and future clinical trial design for a drug candidate.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
39
The slide uses a list-based structure to summarize drug development progress across three distinct assets.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
40
The timeline uses blue and red color coding for different drug programs or status types.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
01
Coupang | Results Presentation Deck | 16 slidesCoupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations 1 hit
02
Coupang | Results Presentation Deck | 16 slidesCoupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations 1 hit
03
Coupang | Results Presentation Deck | 16 slidesCoupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations 1 hit
04
The chart uses a bubble-based growth visualization to represent market size expansion.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · Market Size1 hit
05
The table uses a stair-step visual representation to highlight the compounding nature of cohort spending.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
07
Data points represent millions of members at the end of each quarter.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
09
Highlights 2020 and 2021 as 'Covid Years' with a visual overlay.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
10
Coupang | Results Presentation Deck | 16 slidesCoupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
11
The slide highlights the company's financial trajectory and strategic levers for cash flow improvement.Coupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
Coupang | Results Presentation Deck | 16 slidesCoupang | Results Presentation Deck | 16 slides · Coupang
Pitch deck Investor relations 1 hit